Association of Metformin Use With Osteoarthritis Incidence, Progression, and Joint Arthroplasty Risk in the Knee and Hip: A Systematic Review and Meta-Analysis
Abstract
BACKGROUND: Although hip and knee osteoarthritis (OA) constitutes a major cause of disability globally, disease-modifying therapies do not exist. Preclinical evidence suggests that metformin has disease-modifying potential, but clinical evidence is conflicting. This meta-analysis assessed the effect of metformin on 1) hip/knee OA incidence, 2) radiographic/symptomatic progression, and 3) joint arthroplasty (JA) risk.
METHODS: We systematically searched the PubMed, Web of Science, Embase, and Cochrane Library databases, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Random-effects meta-analyses and qualitative synthesis were performed for the prespecified outcomes.
RESULTS: Evidence from 13 studies enrolling 167,107 cases demonstrated that metformin users had a 33% lower hip/knee OA incidence (pooled risk ratios (RRs) 0.67, 95% confidence intervals (CI) 0.61 to 0.74). Qualitative synthesis indicated reduced magnetic resonance imaging-assessed medial cartilage loss and delayed symptomatic progression with respect to pain, joint function, and quality of life among metformin users. Crucially, metformin was associated with a 43% lower joint arthroplasty risk (pooled risk ratio (RR) 0.57, 95% confidence interval (CI): 0.38 to 0.84), with enhanced protection in those who had pre-existing OA versus those who had diabetes/obesity alone (RR 0.37 versus 0.81) and those receiving more than two years versus two years or less of treatment (RR…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.